Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Chande, Nilesh ^a   Townsend, Cassandra M ^b   Parker, Claire E ^c   Macdonald, John K ^b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIMETABOLITE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

COMPARATIVE STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; INDUCTION CHEMOTHERAPY; META ANALYSIS; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL;

6-MERCAPTOPURINE; ADULT; ANTIMETABOLITES; AZATHIOPRINE; CROHN DISEASE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; MESALAMINE; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFASALAZINE; WITHHOLDING TREATMENT;

EID: 84992462233     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000545.pub5     Document Type: Review

References (112)

1. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator-blind study. Digestive and Liver Disease 2003;35(9):619-27. [3409301]
2. Ardizzone S, Bollani S, Manzionna G, Molteni P, Bianchi Porro G. Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology 1999;116(4):A662-3. [4440581]
3. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8. [3409303]
4. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362(15):1383-95. [3409305]
5. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. Supplementary Appendix. New England Journal of Medicine 2010;362. [3409306]
6. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease - A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics 2015;41(8):734-46. [4440582]
7. Colombel JF, Rutgeerts P, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitzg D, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week 2008. [4440583]
8. Sandborn W, Rutgeerts P, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. SONIC Study: A Randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases 2009;15:S13. [4440584]
9. Sandborn WJ, Rutgeerts PJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. One year data from the Sonic study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology 2009;136(5 Suppl 1):A116. [4440585]
10. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105(2):367-72. [3409310]
11. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Meyer zum Buschenfelde KH, et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology 1992;102(4 Part 2):A 621. [4440586]
12. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66(5):916-22. [3409312]
13. Mantzaris GJ, Ployzou P, Karagiannidis A, Christidou A, Koilakou S, Tsounis D, et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid-dependent Crohn's disease. Gastroenterology 2004;126(4 Suppl 2):A54. [3409314]
14. Hermida C, Cantero J, Moreno-Otero R, Mate-Jimenez J. Methotrexate and 6-mercaptopurine in steroid-dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut 1999;45(Suppl V):A132. [4440587]
15. Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 2000;12(11):1227-33. [3409316]
16. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology 1997;92(12):2203-9. [3409318]
17. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. New England Journal of Medicine 1980;302(18):981-7. [3409322]
18. Present DH, Wisch N, Glass JL, Korelitz BI. The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology 1977;72(5ii):A-91. [4440588]
19. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. American Journal of Gastroenterology 2008;103(9):2284-92. [3409324]
20. Rhodes J, Bainton D, Beck P. Azathioprine in Crohn's disease. Lancet 1970;2(7683):1142. [4440589]
21. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7737):1273-6. [3409326]
22. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77(4 Pt 2):898-906. [3409328]
23. Singleton J, Law D, Kelley M, Mekhjian H, Sturdevant R. National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology 1979;77(4 Pt 2):870-82. [3409329]
24. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69. [3409330]
25. Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77(4 Pt 2):829-42. [3409331]
26. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7731):944-7. [3409333]
27. Willoughby JM, Kumar P, Beckett J, Dawson AM. A double-blind trial of azathioprine in Crohn's disease. Gut 1971;12(10):864. [4440590]
28. Bianchi Porro G, Ardizzone S, Bollani S, Duca A, Manzionna G, Molteni P. Controlled trial comparing intravenous methotrexate and oral azathioprine for chronic active Crohn's disease: preliminary report. Gut 1982;23(10):285. [4440592]
29. Broekman MM, Coenen MJ, Franke B, Derijks LJ, Vermeulen SH, Wong DR, et al. Azathioprine and 6-mercaptopurine are equally effective in thiopurine naive IBD patients. Gastroenterology 2015;148(4 Suppl 1):S269. [4440594]
30. Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, et al. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: Open-label prospective study. Gastroenterology 2007;22:268-74. [3409335]
31. Colombel JF, Lemann M, Bouhnik Y, Duclos B, Soule JC, Lerebours E, et al. Endoscopic healing of Crohn's ileo-colitis with azathioprine. Gastroenterology 2003;124(4 Suppl 1):A196-7. [4440596]
32. Balzola F, Cullen G, Ho GT, Russell RK. Early administration of azathioprine versus conventional management of Crohn's disease: A randomized controlled trial. Inflammatory Bowel Disease Monitor 2013;14(1):23-4. [4440597]
33. Cosnes J, Bourrier A, Bouhnik Y, Laharie D, Nahon S, Bonnet J, et al. Accelerated step-care therapy with early azathioprine (AZA) vs. conventional step-care therapy in Crohn's disease. A randomized study. Gastroenterology 2012;142(5 Suppl 1):S161. [3409337]
34. Costes L, Colombel JF, Mary JY, Duclos B, Veyrac M, Dupas JL, et al. Long term follow-up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. Gastroenterology 2008;134(4 Suppl 1):A134. [4440598]
35. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology 2006;130(4 Suppl 2):A110. [4440599]
36. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. [3409339]
37. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, et al. Randomised clinical trial: Individualised vs. weight-based dosing of azathioprine in Crohn's disease. Alimentary Pharmacology and Therapeutics 2014;39(2):163-75. [4440601]
38. Dassopoulos T, Martin CF, Galanko J, Wolf DC, Dubinsky M, Sandler RS, et al. A randomized trial of metabolite-adjusted versus weight-based dosing of azathioprine (AZA) in Crohn's disease (CD). Gastroenterology 2009;136(5 Suppl 1):T1192. [4440602]
39. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Alimentary Pharmacology and Therapeutics 2003;18:1113-20. [3409341]
40. Eigner W, Vafai-Tabrizi F, Bashir K, Primas C, Vogelsang H. Azathioprine versus mycophenolate mofetil in combination with anti-TNF alpha agents in the management of Crohn's disease. Journal of Crohn's and Colitis 2015;9:S326. [4440604]
41. Israeli E, Goldin E, Fishman S, Konikoff F, Lavy A, Chowers Y, et al. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. Clinical and Experimental Immunology 2015;181(2):362-72. [4440606]
42. Israeli E, Goldin E, Fishman S, Konikoff FM, Lavy A, Chowers Y, et al. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates crohn's disease with low rate of side effects: Results of double blind phase II clinical trial. Gastroenterology 2014;1):S-587. [4440607]
43. Israeli E, Lalazar G, Hemed N, Caraco Y, Goldin E, Ilan Y. Promotion of CD4+CD25+FOXP3+ regulatory cells by oral administration of locally acting delayed release low-dose 6MP formulation alleviated Crohn's disease: Results of phase I/II clinical trial. Gastroenterology 2010;1):S519. [4440608]
44. Khanna R, Levesque BG, Bressler B, Zou G, Stitt L, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial. Journal of Crohn's and Colitis 2014;8:S2-S3. [4440610]
45. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61. [3409345]
46. Lloyd-Still JD. Azathioprine and the treatment of chronic inflammatory bowel disease. Journal of Pediatrics 1990;117(5):732-5. [4440612]
47. Ludwig D, Strange EF. Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. German Imurek Study Group. Zeitschrift für Gastroenterologie 1999;37(11):1085-91. [3409347]
48. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflammatory Bowel Diseases 2009;15:375-82. [3409349]
49. Markowitz J, Grancher K, Kohn N, Daum F. Relationship of leukopenia to 6MP induced remission of Crohn's Disease (CD). Journal of Pediatric Gastroenterology and Nutrition 1998;27(4):465. [4440613]
50. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119(4):895-902. [3409351]
51. Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?. American Journal of Gastroenterology 2001;96(3):782-7. [3409353]
52. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer Zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gastroenterology 1998;114(4 Pt 2):A487. [3409355]
53. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44(5):625-8. [3409356]
54. Balzola F, Cullen G, Ho GT, Russell RK. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Inflammatory Bowel Disease Monitor 2013;14(1):23. [4440614]
55. Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145(4):766-74. [4440615]
56. Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clinical Chemistry 2007;53(7):1306-14. [3409358]
57. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases 1975;20(8):721-6. [4440617]
58. Sans M, Roman ALS, Esteve M, Bermejo F, Garcia-Sanchez V, Torres Y, et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011;140(5 Suppl 1):S109. [4440619]
59. Watson WC, Bukosdky M. Azathioprine in management of Crohn's disease: A randomized cross-over study. Gastroenterology 1974;66:796 (Abstract). [3409360]
60. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99(2):443-6.
61. Avery-Jones F, Lennard-Jones JE, Hinton JM, Reeves WG. Dangers of immuno-suppressive drugs in ulcerative colitis (letter). British Medical Journal 1966;1:1418.
62. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347(8996):215-9.
63. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969;2(7621):612-4.
64. Brooke BN, Javett SL, Davison OW. Further experience with azathioprine for Crohn's disease. Lancet 1970;2(7682):1050-3.
65. Brooke BN, Cave DR, King DW. Place of azathioprine for Crohn's disease. Lancet 1976;1(7968):1041-2.
66. Brown CH, Achkar E. Azathioprine therapy for inflammatory bowel disease. A preliminary report. American Journal of Gastroenterology 1970;54(4):363-77.
67. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. American Journal of Gastroenterology 1994;89(3):362-6.
68. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34(8):1081-5.
69. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343(8908):1249-52.
70. D'Haens G, Callens J, Hiele M, Peeters M, Rutgeerts P. Reduction of neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease. Gastroenterology 1995;108:A809.
71. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997;112(5):1475-81.
72. Drucker WR, Jeejeebhoy KN. Azathioprine: an adjunct to surgical therapy of granulomatous enteritis. Annals of Surgery 1970;172(4):618-26.
73. Fausa O, Gjone E. Azathioprine (Imurel) therapy in Crohn's disease. Acta Medica Scandinavica 1971;190(3):211-2.
74. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Alimentary Pharmacology and Therapeutics 2002;16(7):1225-32.
75. Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. American Journal of Gastroenterology 2008;103(7):1783-800.
76. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
77. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91(4):982-6.
78. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology 2004;2(7):542-53.
79. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
80. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
81. Javett SL, Hoffmann VJ. Azathioprine in acute Crohn's disease. South African Medical Journal 1972;46(38):1369.
82. Kessler BH, Pettei MJ, Weinstein T, Gold DM, Levine JJ. 6-Mercaptopurine (6-MP) in pediatric Crohn's disease: high dose versus conventional dose. Gastroenterology 1995;108:A848.
83. Khan K, Dubinksky M, Ford A, Ullman T, Talley N, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel Disease: A systematic review and meta-analysis. American Journal of Gastroenterology 2011;106:630-42.
84. Korelitz BI, Present DH. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Gastroenterology 1981;80(1):193-6.
85. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Digestive Diseases and Sciences 1985;30(1):58-64.
86. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. American Journal of Gastroenterology 1993;88(8):1198-205.
87. Lémann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Traitment de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine. Gastroentérologie Clinique et Biologique 1990;14(6-7):548-54.
88. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. British Journal of Clinical Pharmacology 1983;16(4):359-63.
89. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenitics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology and Therapeutics 1989;46(2):149-54.
90. Lennard L. The clinical pharmacology of 6-mercaptopurine. European Journal of Clinical Pharmacology 1992;43(4):329-39.
91. Lennard-Jones JE, Williams CB. Azathioprine in the treatment of Crohn's disease. Proceedings of the Royal Society of Medicine 1972;65:291-3.
92. Lennard-Jones JE. Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease. Digestive Diseases and Sciences 1981;26(4):364-8.
93. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99(5):1347-51.
94. Nyman M, Hansson I, Eriksson S. Long-term immunosuppressive treatment in Crohn's disease. Scandinavian Journal of Gastroenterology 1985;20(10):1197-203.
95. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101(1):39-46.
96. Papp JP, Watson DW, Bull FE. Azathioprine treatment in Crohn's disease. American Journal of Gastroenterology 1974;61(2):136-42.
97. Patterson JF, Norton RA, Schwartz RS. Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. American Journal of Digestive Diseases 1971;16(2):327-32.
98. Perrault J, Greseth JL, Tremaine WJ. 6-Mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. Mayo Clinic Proceedings 1991;66(5):480-4.
99. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Annals of Internal Medicine 1989;111(8):641-9.
100. Rosman M, Bertino JR. Azathioprine. Annals of Internal Medicine 1973;79(5):694-700.
101. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology 2008;64:753-67.
102. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109(6):1808-17.
103. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. American Journal of Gastroenterology 1996;91(3):423-33.
104. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117(3):527-35.
105. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
106. Shah MD, Berman WF. Use of azathioprine in nine children with Crohn's disease. Virginia Medical Quarterly 1991;118(3):169-70.
107. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. Journal of Pediatrics 1990;117(5):809-14.
108. Wallensten S, Persson S. Azathioprine therapy for Crohn's disease. Acta Chirurgica Scandinavica 1972;138(5):521-6.
109. Weinshilboum RN, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics 1980;32(5):651-62.
110. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4]
111. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Annals of Internal Medicine 1995;123(2):132-42.
112. Prefontaine E, MacDonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD000545.pub3]